• search
Fill Finish Fill Finish

Fill Finish

Our fill finish capability caters to a wide range of recombinant protein therapeutics.

With over 10,000 sq. meters of fill finish footprint, we can support filling of a wide range of presentations – vials (liquid and lyophilized), pre-filled syringes and autoinjectors.

Our automated fill finish facility efficiently handles high-accuracy, high-viscosity, low-volume protein filing. End-to-end single-use capability enables for faster change over and assurance of cleaning validation.

Our integrated approach to quality management systems enables greater flexibility and leverage pan -organization experience in managing regulatory audits.

Speak to our experts

Fill range and presentation

Fill range is 0.1-100ml, Vials: 2-100 ml, PFS and auto injector: 0.1-1 ml

Technology, formulation, and logistics

  • Technology: peristaltic, rotary piston, end-of-end single-use system, isolator
  • Formulation: liquid, lyophilized
  • Logistics: cold chain, serialization, frozen and liquid API

Protein

mAb, FAb, fusion protein, cytokine, enzyme, hormone, hyper-glycosylated proteins, and derivatized proteins

Why Aurigene Pharmaceutical Services?

100+ successful regulatory audits

10+K sq. meters facility footprints

300+ tech operations professionals

Operations supported by digital infrastructure

Virtual Tour

 

Connect with our scientific experts for your drug discovery, development, and manufacturing needs

We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.

Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.

Country

section

CAPTCHA
この質問はあなたが人間の訪問者であるかどうかをテストし、自動化されたスパム送信を防ぐためのものです。

rightCaptcha

寡核苷酸作为一种新型治疗方式

JULY 02, 2021

寡核苷酸作为一种新型治疗方式

寡核苷酸作为一种治疗类别是发现用于治疗人类疾病的新的重要治疗剂的革命性方法。基于 RNA 的干预有时适用于其他方式不起作用的情况。例如,它可能有助于治疗先天性新陈代谢错误、遗传疾病和罕见病 寡核苷酸疗法是将化学修饰的寡核苷酸用于治疗目的。寡核苷�...

Read More

Methoxy Polyethylene Glycol (m-PEGs)

Aurigene Pharmaceutical Services is a leader in the synthesis of activated MethoxyPolyethyleneGlycol(m-PEGs), With a comprehensive product range and customized services. ...

Read More

Base mediated spirocyclization of quinazoline: one-step synthesis of spiro-isoindolinone dihydroquinazolinones

2020

A novel approach for the spiro-isoindolinone dihydroquinazolinones has been demonstrated from 2- aminobenzamide and 2-cyanomethyl benzoate in the presence of KHMDS as a base to get moderate yields. The reaction has been screened in various bases followed by solvents and a gram scale reaction has also been executed under the given conditions. Based on the controll...

Read More
View All
×

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.

ProceedBack